<< NHLBI awards $11 million to research on the biology of two fatal lung diseases | Pending health reform legislation lacks strategic emphasis on health workforce, say health center CEOs >>
Read in | English | Português | 简体中文 | Nederlands | Bahasa

Effective use of economic incentives and clinical tools help employers to control drug benefit costs

Published on October 8, 2009 at 1:29 AM · No Comments

Employers are effectively controlling drug benefit costs and utilization, according to research findings in the Pharmacy Benefit Management Institute's (PBMI) 2009-2010 Prescription Drug Benefit Cost and Plan Design Report. PBMI's employer survey shows the average rate of increase in drug costs has dropped to 4.4%, the lowest rate of increase since PBMI began conducting the study in 1995.

"Drug benefit management indicators are trending in the right direction as a result of effective use of economic incentives and clinical tools," says Dana H. Felthouse, MBA, PBMI president. "Employer use of multiple-tier drug benefit designs continues to increase for a third year, encouraging plan member use of low cost medications when medically appropriate. Generic dispensing rates increased in both retail and mail, with the average retail rate at 63.5% and the average mail rate at 53.6%."

For the first time, the study notes differences among fully-insured, self-insured, carve-out and carve-in drug benefit programs. For example, self-insured employers and those with carve-out drug plans are most likely to use multi-tiered cost sharing. Another significant difference occurs in management of specialty pharmacy. More carve-out employers than carve-in employers offer a specialty pharmacy benefit, with carve-out employers more likely to use their PBMs as exclusive suppliers of specialty drugs.

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading